All In Biotech

Drug Trial Radar · NCT01983735

Efficacy and Safety of TELMINUVO to Stage 2 Hypertension

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(TELMINUVO TAB.) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension

Last checked: Nov 19, 2026Latest source record: Nov 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 2014

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Chong Kun Dang PharmaceuticalIndustry
Sponsor type
Industry
First posted
Nov 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.

Conditions

  • Hypertension

Interventions

  • TELMINUVO Tab. (80/2.5mg)Drug

    * Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks. * With the others investigation product placebo 1 tab QD 2 weeks.

  • TELMINUVO Tab. (80/5mg)Drug

    * Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks. * With the others investigation product placebo 1 tab QD 6 weeks.

  • S-amlodipine 2.5mgDrug

    * S-amlodipine 2.5mg QD 2 weeks * With the others investigation product placebo 1 tab QD 2 weeks.

  • S-amlodipine 5mgDrug

    * S-amlodipine 5mg QD 6weeks * With the others investigation product placebo 1 tab QD 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Sitting Systolic Blood Pressure (MSSBP)Time frame: After 8 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The catholic university of Korea Seoul St. Mary's hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.